BRIEF—New joint venture to develop KD025 in Asia

Tokyo-based Meiji Seika and New York’s Kadmon Corporation have formed a Japan-domiciled joint venture to exclusively develop and commercialize KD025.

The JV will work towards marketing the ROCK2 blocker in Japan and 12 other Asian countries. Kadmon is eligible for potential development, regulatory and commercial milestone payments, and royalty payments on sales of KD025.

The candidate is being tested in a pivotal clinical trial in the USA, where it has Breakthrough Therapy designation, for the treatment of chronic graft-versus-host disease (cGVHD).